Clinical Trial Update: 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating seven days of neoadjuvant erlotinib followed by adjuvant erlotinib-gemcitabine in pancreatic cancer was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-10-06